Compare NNNN & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNNN | KOD |
|---|---|---|
| Founded | 2021 | 2009 |
| Country | Germany | United States |
| Employees | N/A | 121 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | N/A | 2018 |
| Metric | NNNN | KOD |
|---|---|---|
| Price | $21.20 | $23.22 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $28.29 |
| AVG Volume (30 Days) | 38.7K | ★ 503.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.60 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $446.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.91 | $1.92 |
| 52 Week High | $55.65 | $31.18 |
| Indicator | NNNN | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 40.23 | 41.55 |
| Support Level | $19.25 | $21.19 |
| Resistance Level | $31.44 | $29.17 |
| Average True Range (ATR) | 2.40 | 1.70 |
| MACD | -0.19 | -0.35 |
| Stochastic Oscillator | 0.33 | 8.59 |
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.